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ABSTRACT
Myosin II and its regulator Rho-associated coiled-coil containing protein kinase (ROCK) are essential for
cell invasion and metastatic dissemination. Our recent findings show that this molecular machinery is
also involved in drug resistance in melanoma by playing a dual role: protection of tumor cells from
reactive oxygen species (ROS) and DNA damage (intrinsic), and co-option of myeloid and lymphoid
populations to establish immunosuppression (extrinsic).
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Non-muscle Myosin II (Myosin II hereafter) is a holoenzyme
with actin cross-linking and contractile properties. Myosin II-
driven cell contractility relies on Rho GTPase signaling that
through Rho-associated coiled-coil containing protein kinase
(ROCK) increases phosphorylation of myosin light chain 2
(p-MLC2) and Myosin II activity.1 Myosin II activation gen-
erates contractile force essential for several cellular processes,
including cytokinesis, force-mediated matrix remodeling and,
critically, migration, and metastatic dissemination.2 We have
recently found that apart from these cell-intrinsic functions,
ROCK-Myosin II can shape the microenvironment and polar-
ize macrophages to tumor-promoting phenotypes (CD206+).3
Metastasis is responsible for most deaths of cancer patients.
While there are some therapies that achieve impressive
responses and extend patient survival, these are not long-
lasting due to drug resistance, both intrinsic/primary and
acquired. This is exemplified in cutaneous melanoma, a highly
aggressive and metastatic skin cancer. Most melanoma patients
harbor mutations in the mitogen-activated protein kinase
(MAPK) pathway (BRAF-MEK-ERK) (BRAFV600E being the
most common) and therefore, benefit from targeted therapies
against MAPK pathway (BRAF and MEK inhibitors). However,
resistance inevitably arises in most patients within a year, in
most cases due to ERK restoration.4
Immunotherapies against immune checkpoints programmed
cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), aimed to awake the immune
system that will eliminate the tumor, has proven successful in
a subset of melanoma patients. However, response rates are low
(less than 40%) and a substantial proportion of responders
relapse within 2 years.5 Therefore, metastasis and drug resistance
are major problems that limit achieving long-lasting cures in
melanoma patients.
The last decade has seen a myriad of efforts in deciphering
mechanisms of resistance to targeted and immunotherapies in
melanoma.4 Interestingly, cross-resistance to both MAPK
inhibitors (MAPKi) and immune checkpoint blockers (ICB)
is driven by common alterations at the transcriptional level in
regulators of metastatic features (invasion, epithelial–
mesenchymal transition (EMT), extracellular matrix (ECM)
remodeling).6,7 Therefore, in our latest study, we assessed if
Myosin II and cytoskeletal remodeling could play a role in
therapy-cross-resistance.8
Rho GTPase signaling and cytoskeletal remodeling were top
enriched processes in the phospho-proteome of melanoma cells
after a 24 h treatment of melanoma cells with MAPKi. MAPK
inhibition decreased Myosin II activity (p-MLC2 levels), regard-
less of genetic background (BRAF mutant, BRAF mutant/
PTEN-null, NRAS mutant). Surprisingly, 48 h after MAPK
inhibition Myosin II levels were fully restored or even increased,
while ERK activity was only partially recovered. This uncoupling
of Myosin II fromMAPK suggested that Myosin II could confer
a survival advantage under therapy. In fact, overexpression of
constitutively active MLC2 conferred resistance to BRAFi.
Therefore, under the selective pressure of treatment, Myosin II
uncouples itself from MAPK signaling to provide a survival
advantage.
We next wondered if restoration ofMyosin II in resistant cells
could become a new vulnerability. BRAFi-resistant cells were
much more sensitive to Myosin II blockade using ROCK inhi-
bitors (ROCKi) or ROCK1/2 RNAi. This increased sensitivity
was observed in 2D and 3D environments in a panel of several
models of drug resistance (BRAFi-, BRAFi+MEKi-resistant cell
lines, and patient-derived lines). Direct inhibition of Myosin II
with a specific inhibitor (blebbistatin) and knockdown of either
Myosin II heavy chain (MYH9) or light chains (MYL9/12B) with
RNAi impaired survival of resistant cells. At this point, the
prediction was that cross-resistantmelanomas, having transcrip-
tionally rewired their cytoskeleton, would be refractory to
a second therapy (i.e., immunotherapy) but now much more
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sensitive to Myosin II blockade. In fact, anti-PD-1-resistant cell
lines were more sensitive to Myosin II inhibition with ROCKi,
suggesting that this vulnerability is an intrinsic feature of ther-
apy-resistant cells regardless of the therapy. Survival of patient-
derived cell lines resistant to sequential MAPKi+ICB was also
impaired upon Myosin II inhibition, indicating some level of
cross-resistance.
To assess the clinical relevance of these findings, we
analyzed published transcriptomes of resistant patients.
Half of the patients (on-MAPKi, MAPKi-resistant, and on-
anti-PD-1-resistant) upregulated ROCK-Myosin II path-
way genes. Melanomas resistant to anti-PD-1 had also
higher Myosin II levels before therapy, suggesting its
potential as a biomarker of lack of response. In fact, in
The Cancer Genome Atlas (TCGA) melanoma database we
found that higher expression of ROCK-Myosin II pathway
correlates with poorer prognosis, indicating that higher
Myosin II levels before therapy could identify more
aggressive melanoma cells that would have a survival
advantage later on under therapy.
When we analyzed 12 paired samples from patients before
and after therapy (MAPKi, ICB, or sequential MAPKi+ICB),
using immunohistochemistry (IHC) we measured increased
p-MLC2 levels in the resistant samples. This was accompanied
by changes in the tumor microenvironment: increased matrix
deposition (which could contribute to higher p-MLC2) and
higher numbers of immunosuppressive populations, in parti-
cular CD206+ macrophages and forkhead box P3 (FOXP3+)
regulatory T cells (Tregs). This tumor-supporting microenvir-
onment could explain therapy failure (Figure 1). It will be
important to validate these IHC results in a larger cohort of
patients.
Next, we investigated the mechanism underlying the
increased dependency of resistant cells on Myosin II. We
had previously shown that lowering ROCK-Myosin II
increased reactive oxygen species (ROS) in migrating mela-
noma cells.9 We found that MAPKi-resistant cells harbor
deregulated ROS metabolism and defective DNA damage
repair. We exploited these vulnerabilities and found that





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Novel roles of ROCK-Myosin II in therapy resistance.
Left, diagram showing Myosin II levels after MAPKi treatment. Myosin II is initially reduced but, over time (t), there is profound cytoskeletal remodeling and Myosin II
levels are restored. Middle, therapies (MAPK inhibitors (MAPKi); Anti-programmed cell death protein 1 (PD-1)) initially induce melanoma tumor regression. However,
during adaptation to therapy surviving cells remodel their cytoskeleton and reactivate Myosin II. In resistant cells, Rho-associated coiled-coil containing protein kinase
(ROCK)-Myosin II enhance survival by increasing pro-survival signaling (phosphorylated signal transducer and activator of transcription 3 (p-STAT3)-Mcl-1), thereby
lowering reactive oxygen species (ROS) and DNA damage (intrinsic effects). High p-STAT3 could also contribute to higher levels of PD-1 ligand PD-L1. ROCK-Myosin II
also supports an immunosuppressive microenvironment by promoting forkhead box P3 (FOXP3+) regulatory T cells (Tregs), most likely due to increased transforming
growth factor beta (TGF-β;) and by polarizing macrophages (Mϕ, CD206+, PD-L1+) (extrinsic effects). Resistant tumors present increased extracellular matrix (ECM)
deposition, which could also hamper access of therapies and/or T cells. Right, inhibition of ROCK-Myosin II with a ROCK inhibitor (ROCKi) induces lethal ROS levels
and increased DNA damage, leading to cell death. In addition, ROCKi reduces FOXP3+ Treg numbers and also PD-L1 expression in CD206+ macrophages, relieving
immunosuppression.
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cell cycle arrest in BRAFi-resistant cells compared to the
sensitive counterpart. ROCKi reduced pro-survival signals
mediated by phosphorylated signal transducer and activator
of transcription 3 (p-STAT3)-Mcl-1. All these combined
effects led to cell death (Figure 1).
We then tested ROCKi in pre-clinical therapy-resistant mouse
models. Combination of ROCKi with BRAFi reduced growth of
BRAFi-resistant melanoma xenografts in nude mice. This could be
due to increased intrinsic cell death induced by ROCKi in resistant
cells. Furthermore, ROCKi-treated tumors had reduced p-MLC2
and lower numbers of CD206+ macrophages (total number of F4/
80+ macrophages were unaffected), which could also contribute to
reduced tumor growth in an extrinsic manner. Importantly, using
an experimentalmetastasis assay, we found that pre-treatment with
ROCKi impaired survival of BRAFi-resistant patient-derived mel-
anoma cells in the lung. Altogether, these data suggest that ROCKi
could be used to impair both primary tumor growth andmetastatic
dissemination of resistant melanoma cells.
We next investigated if ROCKi could enhance ICB efficacy.
Indeed, combination of ROCKi with anti-PD-1 induced more
tumor regressions than single anti-PD-1. ROCKi relieved immuno-
suppression by decreasing CD206+ macrophages and FOXP3+
Tregs.Wehavepreviouslydescribed that transforminggrowth factor
beta (TGB-β), a potent immunosuppressor, promotes Myosin II-
driven contractility in melanoma.10 Interestingly, ROCKi reduced
TGB-β levels in immunotherapy-resistant cells in vitro, which could
lead to dampening of immunosuppression in vivo.
Similar to the human setting, we observed variable responses to
anti-PD-1 treatment in mice; therefore, we isolated a non-
responder that was allografted into new recipient mice. In this
model of anti-PD-1 resistance, cancer cells had increased Myosin
II and had polarized all macrophages to CD206+ phenotype.
Importantly, combination ROCKi+anti-PD-1 induced more
tumor regressions and reduced numbers of FOXP3+ Tregs.
Furthermore, ROCKi+anti-PD-1 decreased levels of PD-1 ligand
(CD274, best known as PD-L1) in both tumor cells and CD206+
macrophages (Figure 1), which could contribute to enhanced anti-
PD-1 efficacy. Macrophages are one of the main sources of PD-L1
in themelanomamicroenvironment11 and, therefore, immunosup-
pression. In fact, anti-PD-1/PD-L1 therapies have been suggested to
function also directly on macrophages.12
Our study shows that adaptation to therapy (targeted, ICB) and
development of resistance comes with a cost, since it involves pro-
found cytoskeletal remodeling andMyosin II reactivation. Resistant
cells, therefore, gain a new vulnerability, which can be exploited by
targeting Myosin II with ROCKi (Figure 1). Given the vasodilator
effects of ROCKi,1 further pre-clinical studies assessing dose-
escalation, treatment schedule, and delivery modality (local, anti-
body–drug conjugate) will be needed in order to optimize ROCKi.
Such studieswill aim to assess superior responses of ROCKi as single
therapy, or increase efficacy when combined with standard of care
therapies. Our study raises the possibility that other MAPK-driven
tumors and ICB-resistant cancers could be vulnerable to ROCK-
Myosin II inhibition, which warrants further investigation.
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